8-K: Cardlytics Resolves Bridg Merger Dispute, Announces Positive Preliminary Q4 Results

Cardlytics has settled its dispute with Shareholder Representative Services (SRS) regarding the Bridg merger earnout payments and announced preliminary positive financial results for the fourth quarter of 2023.

Summary

• Cardlytics has reached a settlement agreement with Shareholder Representative Services (SRS) regarding disputes related to the 2021 Bridg merger, specifically concerning earnout payments.
• The settlement involves Cardlytics paying $25 million in cash and issuing 3.6 million shares of common stock to SRS.
• The cash payment will be made in installments: $20 million by January 30, 2024, $3 million by January 31, 2025, and $2 million by June 30, 2025.
• The 3.6 million shares will be issued by February 4, 2024.
• Cardlytics has also announced preliminary unaudited financial results for the fourth quarter of 2023, expecting to meet or exceed previous guidance.
• The company anticipates billings between $131 million and $133 million, revenue between $89 million and $90 million, adjusted contribution between $47 million and $48 million, and adjusted EBITDA between $9.5 million and $10.5 million.
• These preliminary results include approximately $2 million in one-time revenue-related benefits.
• Cardlytics expects to achieve positive adjusted EBITDA for the full year 2023, which will allow them to extend the maturity date of their credit facility to April 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the resolution of a major dispute, better-than-expected preliminary results, and the extension of the credit facility. However, the settlement does involve a cash payment and share dilution, which tempers the overall positive outlook.

Positives

• The settlement with SRS resolves a significant dispute that has impacted Cardlytics for the past year and a half.
• The total settlement value is less than $46 million, which is a positive outcome for the company and its shareholders.
• Cardlytics expects to meet or exceed its previous guidance for Q4 2023.
• The company's focus on cost discipline and efficiency is yielding positive results.
• Achieving positive adjusted EBITDA for 2023 allows for the extension of the credit facility maturity date, providing additional financial flexibility.

Negatives

• The settlement requires a cash payment of $25 million and the issuance of 3.6 million shares, which will dilute existing shareholders.
• The preliminary financial results are unaudited and subject to change upon completion of the quarter-end review and audit.

Risks

• The preliminary financial results are subject to change based on the completion of Cardlytics' quarter-end review process and the audit for the year ended December 31, 2023.
• The company's actual results could differ materially from the forward-looking statements due to various factors, including those detailed in their SEC filings.
• There are limitations associated with the use of non-GAAP financial measures, and these measures may differ from those used by other companies.

Future Outlook

Cardlytics expects to achieve positive adjusted EBITDA for the full year 2023, which will allow them to extend the maturity date of their credit facility to April 2025. The company is looking forward to focusing solely on the business moving forward.

Management Comments

• Cardlytics CEO Karim Temsamani stated he is delighted to resolve this significant issue that has greatly impacted Cardlytics.
• Cardlytics CFO Alexis DeSieno stated that the company expects to meet or exceed previous guidance and that their focus on cost discipline and efficiency is paying off.

Industry Context

The resolution of the dispute and the positive preliminary results could improve investor confidence in Cardlytics, especially given the competitive landscape in digital advertising and the importance of financial stability for growth.

Comparison to Industry Standards

• While specific competitor data is not provided, the positive adjusted EBITDA and revenue growth suggest Cardlytics is performing well compared to industry averages, especially given the challenges of the past year and a half.
• The ability to extend the credit facility maturity date is a positive sign of financial health, which is crucial for companies in the technology sector.

Legal Proceedings

• Cardlytics will dismiss its lawsuit against SRS in the Delaware Court of Chancery with prejudice.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of 3.6 million shares.
• Shareholders will benefit from the resolution of the dispute and the positive financial outlook.
• Employees may benefit from the improved financial stability of the company.
• Creditors will benefit from the extension of the credit facility maturity date.

Next Steps

• Cardlytics will finalize its Q4 2023 financial results and complete the audit for the year ended December 31, 2023.
• The company will issue 3.6 million shares of common stock to SRS by February 4, 2024.
• Cardlytics will make the remaining cash payments to SRS by January 31, 2025, and June 30, 2025.
• The company will extend the maturity date of its credit facility to April 2025.

Key Dates

Keywords

Cardlytics, Settlement Agreement, Bridg Merger, Earnout Payments, Shareholder Representative Services, SRS, Q4 2023 Results, Adjusted EBITDA, Credit Facility, Financial Results